Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cowealth Medical China CoSHSE:603122 -0.40%56 PB Ratio is 4.75 as of Aug. 14, 2026, which is 64% above its 10-year median of 2.90. GuruFocus rates SHSE:603122 with a GF Score™ of 56/100 and a GF Value™ of ¥3.80 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 194 Medical Diagnostics & Research companies, Cowealth Medical China Co ranks worse than 76.8% on this metric.
The historical rank and industry rank for Cowealth Medical China Co's PB Ratio or its related term are showing as below:
SHSE:603122'
s PB Ratio Range Over the Past 10 Years
Min: 1.68 Med: 2.9 Max: 10.48
Current: 4.75
During the past 9 years, Cowealth Medical China Co's highest PB Ratio was 10.48. The lowest was 1.68. And the median was 2.90.
SHSE:603122's PB Ratio is ranked worse than 76.8% of 194
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.21
vs SHSE:603122: 4.75
During the past 12 months, Cowealth Medical China Co's average Book Value Per Share Growth Rate was -10.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -3.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 2.30% per year.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Cowealth Medical China Co was 6.90% per year. The lowest was -3.50% per year. And the median was 3.55% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Cowealth Medical China Co PB Ratio Related Terms
Cowealth Medical China Co PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:603122 vs TMO, DHR, IDXX: PB Ratio Comparison
For the Diagnostics & Research subindustry, Cowealth Medical China Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cowealth Medical China Co PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Cowealth Medical China Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Cowealth Medical China Co's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Cowealth Medical China Co (SHSE:603122) has a PB Ratio of 4.75 as of Aug. 14, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cowealth Medical China Co and its competitors. This is 64% above median its historical median of 2.90. Over the past decade, Cowealth Medical China Co's PB Ratio has ranged from 1.68 to 10.48. According to the industry distribution chart, Cowealth Medical China Co ranks #149 out of 194 companies in the Medical Diagnostics & Research industry, placing it in the top 76.8%.
Is Cowealth Medical China Co's PB Ratio too high?
Cowealth Medical China Co's current PB Ratio of 4.75 is 64% above median its 10-year median of 2.90. Over the past 10 years, this metric has ranged from a low of 1.68 to a high of 10.48. The Medical Diagnostics & Research industry median PB Ratio is 2.21. Cowealth Medical China Co's value of 4.75 is 114.9% above this industry median. Based on the distribution chart, Cowealth Medical China Co ranks #149 out of 194 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Cowealth Medical China Co has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cowealth Medical China Co's PB Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Cowealth Medical China Co ranks #149 out of 194 companies for PB Ratio. This places Cowealth Medical China Co in the lower half of its industry. The industry median PB Ratio is 2.21. Cowealth Medical China Co's value of 4.75 is 114.9% above this benchmark. Historically, Cowealth Medical China Co's own PB Ratio has ranged from 1.68 to 10.48 over the past decade. While the company's 10-year median is 2.90 vs. the industry median of 2.21, Cowealth Medical China Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Diagnostics & Research company?
The median PB Ratio among Medical Diagnostics & Research companies is 2.21, based on 194 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cowealth Medical China Co's current PB Ratio of 4.75 is 114.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cowealth Medical China Co and its competitors. For the Medical Diagnostics & Research industry, the median PB Ratio is 2.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cowealth Medical China Co's current PB Ratio is 4.75, which is 64% above median its own 10-year median of 2.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cowealth Medical China Co stock overvalued right now?
Based on GuruFocus' analysis, Cowealth Medical China Co (SHSE:603122) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥3.80, compared to a current price of ¥12.45 — trading 227.6% above its estimated fair value. The current PB Ratio is 4.75, which is 64% above median its 10-year median of 2.90 and 114.9% above the Medical Diagnostics & Research industry median of 2.21. Cowealth Medical China Co's overall GF Score™ is 56/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Cowealth Medical China Co (SHSE:603122), the current PB Ratio is 4.75 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cowealth Medical China Co (SHSE:603122) Overvalued in 2026?
Based on GuruFocus' analysis, Cowealth Medical China Co stock appears to be overvalued.
The current stock price of ¥12.45 is trading 227.6% above its estimated GF Value™ of ¥3.80.
GuruFocus considers Cowealth Medical China Co to be Significantly Overvalued.
Key valuation signals for SHSE:603122:
PB Ratio: 4.75 (64% above median its 10-year median of 2.90)
GF Value™: ¥3.80 vs. price of ¥12.45 (227.6% above fair value)
Industry Position: 114.9% above the Medical Diagnostics & Research median (#149 of 194)
No single metric tells the full story. See the SHSE:603122 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603122 has been successfully added to your 
